Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (FULC) has announced the granting of inducement stock options to a new employee under its 2022 Inducement Stock Incentive Plan. The company granted 63,000 options to purchase common stock at an exercise price of $3.81 per share, which was the closing price on February 3, 2025.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters. The vesting is contingent upon continued employment with Fulcrum through the applicable dates. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its upcoming participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will engage in a fireside chat during the virtual event on February 12, 2025, at 1:20 pm ET.

Interested parties can access the webcast through a direct link or via the 'Events and Presentations' section of Fulcrum's investor relations website. The presentation recording will remain available for a minimum of 30 days following the event on the company's website.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced its participation in three major healthcare conferences this December. The company will present at the Piper Sandler 36th Annual Healthcare Conference on December 3 with a fireside chat at 12:00 pm ET in New York, the Citi 2024 Global Healthcare Conference on December 4 in Miami, and the Evercore ISI 7th Annual HealthCONx Conference on December 5 in Miami. The Piper Sandler fireside chat webcast will be available on Fulcrum's website for at least 30 days after the presentation.

Fulcrum Therapeutics (FULC) reported Q3 2024 financial results and business updates. The company continues to progress with patient enrollment in the Phase 1b PIONEER trial of pociredir for sickle cell disease. Cash position stood at $257.2 million as of September 30, 2024, with runway extending into 2027. Q3 net loss was $21.7 million, compared to $24.0 million in Q3 2023. R&D expenses decreased to $14.6 million from $18.2 million year-over-year. The company suspended losmapimod development following September's REACH trial results and is now focusing on pociredir development and other early discovery programs.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in the Stifel Healthcare Conference. The company's management will engage in a fireside chat on November 19th at 3:35 pm ET in New York City, along with one-on-one investor meetings.

The fireside chat will be available via webcast, accessible through both a direct link and the Events and Presentations section of Fulcrum's website. A replay will remain available for at least 30 days after the presentation.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for rare diseases, has scheduled its third quarter 2024 financial results release for Wednesday, November 13, 2024, before U.S. market open. The company will host a conference call and webcast at 8:00 a.m. ET to discuss results and provide corporate updates. Participants can register online to receive dial-in details and a unique PIN. The webcast will be available through the company's Investor Relations section, with an archived replay accessible afterward.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of non-statutory stock options to two new employees. These grants were made under the company's 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

The new employees received an aggregate of 90,000 options to purchase Fulcrum's common stock at an exercise price of $3.57 per share, which was the closing price on the grant effective date, October 7, 2024. Each option has a ten-year term and vests over four years, with 25% vesting on the first anniversary of the employee's start date and an additional 6.25% vesting quarterly over the following three years, subject to continued employment.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has announced the granting of non-statutory stock options to three new employees. The grants were made under the company's 2022 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). An aggregate of 130,800 options were granted to purchase shares of Fulcrum's common stock at an exercise price of $8.63 per share, which was the closing price on September 9, 2024, the grant effective date.

Each option has a ten-year term and vests over four years, with 25% vesting on the first anniversary of the employee's start date and an additional 6.25% vesting quarterly over the following three years, subject to continued employment.

Fulcrum Therapeutics (NASDAQ: FULC) announced that its Phase 3 REACH trial for losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) failed to meet its primary endpoint. The trial showed no significant improvement in relative surface area (RSA) compared to placebo at week 48. Secondary endpoints also failed to achieve statistical significance. As a result, Fulcrum plans to suspend the losmapimod program in FSHD.

Key results include:

• Losmapimod group: 0.013 improvement in RSA
• Placebo group: 0.010 improvement in RSA
• No significant differences in muscle fat infiltration, shoulder abductor strength, or patient-reported outcomes

Despite this setback, Fulcrum remains financially stable with $273.8 million in cash and equivalents as of June 30, 2024. The company will redirect its resources to advance pociredir for sickle cell disease and other early-stage programs.